Normal view MARC view ISBD view

Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy

In Cancer Research, Statistics, and Treatment
By: Patil VM.
Contributor(s): Noronha V | Joshi A | Talreja V | Dhumal S | Menon N | Abhyankar A | Dsouza H | Singh GK | Bhattacharjee A | Ghosh-Laskar S | Pai P | Chaturvedi P | Nair D | Chaukar D | D'cruz A | Shetty P | Moiyadi A | Prabhash K [Corresponding Author ].
Material type: materialTypeLabelArticlePublisher: 2020Description: .Subject(s): Adverse event | Esthesioneuroblastoma | Induction | Neoadjuvant | Sinonasal | Sinonasal neuroendocrine carcinoma In: Cancer Research, Statistics, and Treatment Vol. 3, no. 2, p. 201-206.Summary: Background: Sinonasal tumors are a rare group of neoplasms with limited data available regarding their treatment. Objectives: To estimate the 5 year outcomes and late adverse events of locally advanced sinonasal tumors treated with neoadjuvant therapy (NACT) followed by local therapy. Methods: Twenty‑five patients with locally advanced esthesioneuroblastoma or sinonasal neuroendocrine tumors treated between August 2010 and August 2014 with NACT followed by local therapy were selected. The 5‑year outcome and late adverse events (CTCAE version 4.02) were noted. Progression‑free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. COX regression analysis was used to identify factors impacting PFS and OS. Results: The median follow‑up was 5.15 years. The 5‑year PFS in the esthesioneuroblastoma cohort and in the sinonasal neuroendocrine carcinoma (SNEC) cohort was 63.5% (95% confidence interval [CI]: 28.9–84.7) and 34.6% (95% CI: 10.1–61.1), respectively (P = 0.1). The only factor impacting PFS on multivariate analysis was a response to NACT (P = 0.033). The 5‑year OS in the esthesioneuroblastoma cohort and in the SNEC cohort was 91.7% (95% CI: 53.9–98.9) and 46.2% (95% CI: 19.2–69.6), respectively (P = 0.024). Any grade late adverse events were seen in 20 patients (80%). Metabolic late adverse events were seen in 19 patients (76%). Conclusion: NACT in advanced sinonasal cancers is associated with an improvement in 5‑year outcomes. However, late side effects, especially metabolic, are seen in these patients and should be evaluated during follow‑up.
TMC TMH - HBNI
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR20167

Address for Corresponding Author: kumarprabhashtmh@gmail.com

Background: Sinonasal tumors are a rare group of neoplasms with limited data available regarding their treatment.

Objectives: To estimate the 5 year outcomes and late adverse events of locally advanced sinonasal tumors treated with neoadjuvant therapy (NACT) followed by local therapy.

Methods: Twenty‑five patients with locally advanced esthesioneuroblastoma or sinonasal neuroendocrine tumors treated between August 2010 and August 2014 with NACT followed by local therapy were selected. The 5‑year outcome and late adverse events (CTCAE version 4.02) were noted. Progression‑free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. COX regression analysis was used to identify factors impacting PFS and OS.

Results: The median follow‑up was 5.15 years. The 5‑year PFS in the esthesioneuroblastoma cohort and in the sinonasal neuroendocrine carcinoma (SNEC) cohort was 63.5% (95% confidence interval [CI]: 28.9–84.7) and 34.6% (95% CI: 10.1–61.1), respectively (P = 0.1). The only factor impacting PFS on multivariate analysis was a response to NACT (P = 0.033). The 5‑year OS in the esthesioneuroblastoma cohort and in the SNEC cohort was 91.7% (95% CI: 53.9–98.9) and 46.2% (95% CI: 19.2–69.6), respectively (P = 0.024). Any grade late adverse events were seen in 20 patients (80%). Metabolic late adverse events were seen in 19 patients (76%).

Conclusion: NACT in advanced sinonasal cancers is associated
with an improvement in 5‑year outcomes. However, late side effects, especially metabolic, are seen in these patients and should be evaluated during follow‑up.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha